Becton, Dickinson and Company (BDX) is currently undergoing notable transitions with significant executive retirements and CFO transition plan. Amidst these changes, the company is also focusing on enriching its product portfolio, notably with the successful completion of combining its Biosciences & Diagnostic Solutions business with
Waters Corporation. Efforts are being made towards securing the CE Mark for
Liverty TIPS Stent, along with announcement of new AI-enabled Healthcare solutions. However, the company’s shares recently experienced a slide, leading to lowered price targets from analysts.
BDX's valuation is being keenly assessed taking into account its recent share price movements and business separation plans. Yet, despite the immediate decline, numerous analyses state that the company’s shares are significantly undervalued, indicating a potential for long-term investment opportunity. Focus is also turning towards the upcoming financial results of BDX, with anticipation for Q1 earnings. BDX has also made plan to make substantial financial contributions towards the U.S. pharmaceutical supply chain for Biologic Drugs. Meanwhile,
BD's new EU liver stent aims to provide tailored care, and the company also continues to make strides in sustainability, notably with recycling progress.
Becton Dickinson and BDX News Analytics from Mon, 14 Jul 2025 07:00:00 GMT to Sat, 11 Apr 2026 03:38:08 GMT -
Rating -2
- Innovation 5
- Information 8
- Rumor -4
